---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-017398"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:17:26.776037+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Capricor Q3 2022 net loss $6.4M, cash $46.6M; HOPE-3 enrollment on track

## Summary
- Revenue $1.6M from Nippon Shinyaku upfront recognition; net loss $0.26/shr vs $0.17/shr a year ago.
- Cash and securities $46.6M as of Sept 30, 2022, up from $34.9M at year-end 2021.
- Raised ~$1.9M through ATM at avg $5.72/shr; cash runway expected into Q2 2024.
- HOPE-3 Phase 3 for CAP-1002 in DMD enrollment progressing; interim analysis expected mid-2023.
- Positive one-year HOPE-2 open label extension data presented at WMS 2022; new StealthX exosome vaccine data shown.

## SEC filing metadata
- accession: 0001558370-22-017398
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/0001558370-22-017398-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/capr-20221110x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-017398
- JSON: https://secwatch.observer/filing/0001558370-22-017398.json
- Plain text: https://secwatch.observer/filing/0001558370-22-017398.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported third quarter ended September 30, 2022 results: revenue approximately $1.6 million, net income approximately $6.4 million, EPS $0.26 per share.
  - Period: third quarter ended September 30, 2022
  - Revenue: approximately $1.6 million
  - Net income: approximately $6.4 million
  - EPS: $0.26 per share
  - Result: reported results
  source text: For the three months ended September 30, 2022, the Company reported revenue of approximately $1.6 million compared with zero for the three months ended September 30, 2021. Operating expenses: Total operating expenses for the three months ended September 30, 2022, were approximately $8.1 million compared with approximately $4.3 million for the three months ended September 30, 2021. The Company reported a net loss of approximately $6.4 million, or $0.26 per share, for the third quarter of 2022, compared to a net loss of approximately $3.9 million, or $0.17 per share, for the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000155837022017398/0001558370-22-017398-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.